Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.76%
+0.52%
-3.65%
+1.33%
+16.74%
LYRA
Lyra Therapeutics Inc.
$9.00
Login to display Lyra Therapeutics Inc. (LYRA) recommendation from the last 90 days from financial news and social media.
LYRA Total Score
Chart
$0.27 (+3233.33%)
This Indicator assigning LYRA risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.
Risks Indicators
High volatilty
Risk Volatility
LYRA has Medium Risk Level
Click here to check what is your level of risk
LYRA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
LYRA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
LYRA Street view is extremely bullish and have positive views on the near-term outlook
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.76%
+0.52%
-3.65%
+1.33%
+16.74%
LYRA
Lyra Therapeutics Inc.
Current Price
$9.00
Strong Sell
Login to view Lyra Therapeutics Inc. (LYRA) recommendation from the last 90 days from financial news and social media.
Chart
$0.27 (+3233.33%)
LYRA Latest Analysis
Lyra Therapeutics Raises $5 Mln In Direct Offering Eyes $9.8 Mln Via Warrant Exercises . (RTTNews) - Lyra Therapeutics Inc. (LYRA) announced Friday a registered direct offering of 423372 shares of common stock (or pre-funded warrants) priced at-the-market under Nasdaq rules along with a concurrent private placement of warrants to purchase up to 846744 shares.
Fri Jun 27, 2025
Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement stock falls 22%.
Fri Jun 27, 2025
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules. ) (Lyra or the Company) a clinical-stage biotechnology company developing long-acting anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS) today announced that it has entered into a definitive agreement for the purchase and sale of 423372 shares of common stock (or pre-funded warrants in lieu thereof) in
Fri Jun 27, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
LYRA Stock trends
LYRA Stock performance
LYRA Stock analysis
LYRA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings